• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Chosa Oncology

0.88 SEK

-2.44 %

Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.44 %
-1.13 %
+13.29 %
-7.58 %
-17.17 %
+29.12 %
-43.91 %
-95.45 %
-93.04 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Read more
Market cap
77.14M SEK
Turnover
204.59K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27/8
2026

Interim report Q2'26

19/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release6/1/2026, 6:30 PM

Chosa Oncology AB: CHOSA presenterar data vid ASCO som validerar Platin-DRP på NanoString-plattformen och visar signifikant prediktion av total överlevnad i en fas III-studie inom lungcancer

Chosa Oncology
Regulatory press release6/1/2026, 6:30 PM

Chosa Oncology AB: CHOSA och AIDA presenterar data vid ASCO 2026 som visar upp till 78 % patologisk komplett respons (pCR) vid bröstcancer med hjälp av kombinerade, integrerade biomarkörer för taxan och platin

Chosa Oncology
Regulatory press release6/1/2026, 6:30 PM

Chosa Oncology AB: CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study

Chosa Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/1/2026, 6:30 PM

Chosa Oncology AB: CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers

Chosa Oncology
Regulatory press release5/27/2026, 12:40 PM

Kommuniké från årsstämma den 27 maj 2026 i Chosa Oncology AB

Chosa Oncology
Regulatory press release5/27/2026, 12:40 PM

Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB

Chosa Oncology
Regulatory press release5/27/2026, 6:30 AM

CHOSA Oncology AB - publicerar delårsrapport för första kvartalet 2026.

Chosa Oncology
Regulatory press release5/6/2026, 1:06 PM

Chosa Oncology AB: CHOSA Oncology publishes the Annual and Consolidated Financial Statements for the financial year 2025

Chosa Oncology
Regulatory press release5/6/2026, 1:06 PM

Chosa Oncology AB: CHOSA Oncology publicerar års- och koncernredovisningen för räkenskapsåret 2025

Chosa Oncology
Press release4/27/2026, 11:00 AM

Chosa Oncology AB: CHOSA Oncology samarbetar med Mount Sinai, New York för att testa biomarkör som vägleder platin-immunterapi vid lungcancer

Chosa Oncology
Press release4/27/2026, 11:00 AM

Chosa Oncology AB: CHOSA Oncology partners with Mount Sinai, New York to test biomarker guiding platin-immunotherapy in lung cancer

Chosa Oncology
Regulatory press release4/24/2026, 12:30 PM

Notice of annual general meeting in Chosa Oncology AB

Chosa Oncology
Regulatory press release4/24/2026, 12:30 PM

Kallelse till årsstämma i Chosa Oncology AB

Chosa Oncology
Press release4/24/2026, 10:26 AM

Chosa Oncology AB: CHOSA presenterar ny Platin-DRP®-data vid ASCO 2026

Chosa Oncology
Press release4/24/2026, 10:26 AM

Chosa Oncology AB: CHOSA to present new Platin-DRP® data at ASCO 2026

Chosa Oncology
Regulatory press release3/26/2026, 12:00 PM

Chosa Oncology AB: CHOSA förutsäger positiva data för Platin-DRP® som predicerar total överlevnad vid avancerad NSCLC vid European Lung Cancer Congress 2026

Chosa Oncology
Regulatory press release3/26/2026, 12:00 PM

Chosa Oncology AB: CHOSA presents positive data on Platin-DRP® predicting overall survival in advanced NSCLC at the European Lung Cancer Congress 2026

Chosa Oncology
Press release3/19/2026, 7:45 AM

Chosa Oncology AB: CHOSA presenterar data om Platin-DRP som kan förutsäga överlevnadsvinst av carboplatin och cisplatin hos patienter med avancerad NSCLC från en fas III-studie vid European Lung Cancer Congress 2026

Chosa Oncology
Press release3/19/2026, 7:45 AM

Chosa Oncology AB: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress

Chosa Oncology
Regulatory press release2/26/2026, 7:30 AM

Chosa Oncology AB: CHOSA Oncology AB - publicerar bokslutskommuniké för 2025.

Chosa Oncology